

# TABLE OF CONTENTS

## Oncology and Nephrology Care I . . . . . 1

Oncology and Nephrology Care I Panel . . . . .	3
--	---

## Multiple Myeloma

*By Elizabeth Koselke, Pharm.D., BCOP; and Christopher A. Fausel, Pharm.D., FHOPA, BCOP*

Introduction . . . . .	7
Epidemiology . . . . .	7
Risk Factors . . . . .	8
Pathophysiology . . . . .	8
Clinical Presentation . . . . .	8
Molecular Biology . . . . .	8
Diagnosis . . . . .	9
Staging and Risk Stratification . . . . .	9
Response Criteria . . . . .	10
Treatment Strategies . . . . .	11
Supportive Care . . . . .	14
Role of the Pharmacist . . . . .	19
Conclusion . . . . .	20
References . . . . .	21
Self-Assessment Questions . . . . .	23

## Breast Cancer

*By Kellie Jones Weddle, Pharm.D., FCCP, FHOPA, BCOP*

Introduction . . . . .	27
Screening . . . . .	27
Risk Factors and Prevention . . . . .	28
Diagnosis . . . . .	29
Types of Breast Cancer . . . . .	29
Prognostic Factors . . . . .	30
Staging . . . . .	30
Early-Stage-Disease Treatment . . . . .	31
Metastatic-Disease Treatment . . . . .	36
Future Directions . . . . .	41
Conclusion . . . . .	42
References . . . . .	42
Self-Assessment Questions . . . . .	45

## Oncology and Nephrology Care II . . . . . 49

Oncology and Nephrology Care II Panel . . . . .	51
---	----

## Anticancer Therapy–Induced Nausea and Vomiting

*By Rowena N. Schwartz, Pharm.D., FHOPA, BCOP*

Introduction . . . . .	55
Risk Factors for CINV . . . . .	57
Drug Therapies for CINV Prevention and Management . . . . .	59

Nonpharmacologic Prevention and Management of CINV . . . . .	66
Prevention of CINV . . . . .	67
Treatment Considerations for Selected Patients and Patient Populations . . . . .	70
Conclusion . . . . .	71
References . . . . .	72
Self-Assessment Questions . . . . .	74

## Anemia Management in the Biosimilar Era

*By John B. Bossaer, Pharm.D., BCOP, BCPS*

Introduction . . . . .	79
Goals of Anemia Treatment . . . . .	84
Updates in Managing Nutritional Deficiencies in Anemia . . . . .	85
Biosimilars . . . . .	89
Managing Anemia with ESAs . . . . .	90
Anemia Management in Special Populations . . . . .	92
Conclusion . . . . .	95
References . . . . .	96
Self-Assessment Questions . . . . .	98

## Oncology and Nephrology Care III . . . . . 103

Oncology and Nephrology Care III Panel . . . . .	105
--	-----

## Nephrotic Syndrome

*By Estella M. Davis, Pharm.D., FCCP, BCPS; and Stacey K. Dull, Pharm.D., BCPS*

Introduction . . . . .	109
Pathophysiology of Manifestations of NS . . . . .	111
Diagnostic Evaluation of NS . . . . .	112
Management of Common Complications of NS . . . . .	113
Immunosuppressive Therapies to Manage Glomerulopathies That Exhibit NS . . . . .	119
Glomerular Diseases Exhibiting NS Requiring Immunosuppression to Induce Remission . . . . .	122
Monitoring and Precautions for Immunosuppressive Therapies . . . . .	123
Conclusion . . . . .	126
References . . . . .	126
Self-Assessment Questions . . . . .	128

## Drug-Induced Kidney Injury

*By Mariann D. Churchwell, Pharm.D., FCCP, BCPS*

Introduction . . . . .	133
Presentation of DIKD . . . . .	137
Pathophysiology . . . . .	138
Conclusion . . . . .	150
References . . . . .	150
Self-Assessment Questions . . . . .	153

**Oncology and Nephrology Care IV . . . . . 157**

Oncology and Nephrology Care IV Panel . . . . . 159

**Interactive Case: Monitoring Patients on Oral Chemotherapy**

*By Julianne O. Darling, Pharm.D., BCOP*

Selected Resources for Oral Oncolytic Financial Assistance . 164

Interactive Case: Monitoring Patients on Oral Chemotherapy 164

Hyperlink to Activity . . . . . 164

Self-Assessment Questions . . . . . 166

**Interactive Case: Cancer Immunotherapy and Long-Term Toxicity**

*By Heidi D. Finnes, Pharm.D., FHOPA, BCOP*

Interactive Case: Cancer Immune Checkpoint Inhibitors and Long-term Toxicity . . . . . 170

Hyperlink to Activity . . . . . 170

Self-Assessment Questions . . . . . 172

**Interactive Case: Drug Dosing in Kidney Disease**

*By Rebecca Maxson, Pharm.D., BCPS*

Interactive Case: Drug Dosing in Kidney Disease . . . . . 177

Hyperlink to Activity . . . . . 177

Self-Assessment Questions . . . . . 180